← Back to Search

Other

Ketamine and Dexmedetomidine group for Anterior Cervical Discectomy and Fusion

Phase 4
Waitlist Available
Led By Mohamed Abdeldayem, MD
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women 18- to 80-years old
ASA 1, 2, 3
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights

Study Summary

This trial will compare two types of anesthesia commonly used in ACDF surgery to see which is better. One group will receive a narcotic and the other will not. The goal is to see if eliminating the narcotic results in a safer surgery with less pain medication needed afterwards.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Unacceptable Movement Under General Anesthesia
Secondary outcome measures
Hemodynamic Stability
Narcotic Consumption
Quality of Recovery
+1 more

Trial Design

2Treatment groups
Active Control
Group I: Ketamine and Dexmedetomidine groupActive Control2 Interventions
dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound. Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
Group II: Remifentanil GroupActive Control1 Intervention
Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
485 Previous Clinical Trials
149,841 Total Patients Enrolled
Mohamed Abdeldayem, MDPrincipal InvestigatorUniversity of Arkansas

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025